The US DoJ conditionally approves a merger in the healthcare industry (CVS / Aetna)

The DOJ's approval of the CVS/Aetna Merger and vertical innovation by incumbents* Last week, the DOJ cleared the merger of CVS Health and Aetna (conditional on Aetna’s divesting its Medicare Part D business), a merger that, as I previously noted at a House Judiciary hearing, “presents a creative effort by two of the most well-informed and successful industry participants to try something new to reform a troubled system.” (My full testimony is available here). Of course it’s always possible that the experiment will fail — that the merger won’t “revolutioniz[e] the consumer health care experience” in the way that CVS and Aetna are hoping. But it’s a low (antitrust) risk effort to address some of the challenges confronting the healthcare industry — and apparently the DOJ agrees. I discuss the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • International Center for Law & Economics (Portland)

Quotation

Geoffrey Manne, The US DoJ conditionally approves a merger in the healthcare industry (CVS / Aetna), 10 October 2018, e-Competitions Bulletin January 2019, Art. N° 88708

Visites 64

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues